Purpose

This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease.

Category

IRB Number
20180668HU
NCT Number
NCT03697148
Sponsor
ECOG-ACRIN Cancer Research Group -



Study Contact

Principal Investigator
Chul Ha

Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu

Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu

Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu

Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu

Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu



Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

    • Recently diagnosed with prostate cancer for whom definitive surgical treatment is indicated

Exclusion Criteria

    • Not suitable to undergo MRI or receive gadolinium-based contrast agent (severe, untreatable claustrophobia; MRI-incompatible metallic objects or implanted medical devices; renal failure; weight greater than allowable by scanner per institutional standard practice)
    • Prior surgical and/or non-surgical treatment for prostate cancer
    • Prior hip replacement or other major pelvic surgery

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Diagnostic
Masking
None (Open Label)
Condition
  • Prostate Carcinoma

    • Arm Groups

    ArmDescriptionIntervention
    Experimental

    Diagnostic (mpMRI)

    		Patients undergo mpMRI within 3 months prior to schedule surgery.
  • Diagnostic Test: Multiparametric Magnetic Resonance Imaging

    Undergo mpMRI

    Other names:

    • MP-MRI
    • Multi-parametric MRI
    • Multiparametric MRI

    •